DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Journey Medical Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$5.17+0.21 (+4.13%)
Close on Oct 19, 2026
- Market cap
- $142.14M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.03 (−28.19%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Journey Medical Corp grew revenue 20.9% to $68.18M over the twelve months to Jun 30, 2026.
Revenue
$68.18M
+20.9% vs. a year earlier
Operating income
-$3.01M
TTM Q2 2026
EPS, diluted
-$0.23
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $142.14M
- P/E ratio
- –
- Price to sales
- 2.08
- Price to book
- 4.43
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $68.18M
- Net income
- -$6.10M
- EPS, diluted
- -$0.23
- Book value per share
- $1.17
- Diluted shares
- 27M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$68.18M+20.9% YoY
Gross profit
$44.63M+18.9% YoY
Operating income
-$3.01M
Net income
-$6.10M
EPS, diluted
-$0.23
Free cash flow
–
Reported periodTrailing twelve months